Trial · NCT07537751
Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis
NCT07537751, Not applicable, Completed, Noura Abdelmoneim Mohammed Elseessy
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis. Trials, record NCT07537751. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07537751
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis
- NCT number
- NCT07537751
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 40 participants, actual
- Lead sponsor
- Noura Abdelmoneim Mohammed Elseessy
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Crisaborole 2% topical ointment, Fluticasone propionate 0.05% topical cream
- First posted
- 2026-04-17
- Last updated
- 2026-04-17
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage improvement in objective SCORAD from baseline to Week 6 | Baseline to Week 6 of treatment | Objective SCORAD is assessed at baseline and Week 6, and the percentage improvement is calculated as the change from baseline divided by the baseline score, expressed as a percentage, to compare treatment response between the two groups. |
| Secondary | Change in Investigator's Static Global Assessment (ISGA) | Baseline to Week 6 | ISGA score (0-4) is assessed at baseline and Week 6 to evaluate global clinical severity and response to treatment in each arm. |
| Secondary | Change in peak pruritus numerical rating scale | Baseline to Week 18 | Peak pruritus is measured using an 11-point numerical rating scale (0 = no itch, 10 = worst imaginable itch) completed by patients or their parents at baseline, Week 6, and during follow-up. |
| Secondary | Disease-free survival (relapse-free rate) | Week 6 to Week 18 | Among patients achieving \>75% improvement in SCORAD at Week 6, the proportion remaining free of relapse (no increase in SCORAD \>50% over the Week 6 value) is assessed using survival analysis during the 12-week follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07537751
GET https://conductscience.org/api/trials/v1/NCT07537751/registered